Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum
Rattachement africain : us, it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Patients with indolent conjunctival lymphomas exhibit good prognosis, with exceptional cases of dissemination, and are suitable candidates for intralesional therapies. We report the first prospective phase 2 trial using intralesional rituximab supplemented with autologous serum in adults with relapsed/refractory indolent CD20+ lymphoma of the conjunctiva (NCT01514344). Patients received 4 weekly intralesional injections of rituximab, followed by 6 monthly injections; 500 μL of autologous serum was added to rituximab in patients with lymphoma unresponsive to weekly doses. Safety, activity, and antitumor effect of autologous serum were investigated. Twenty patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma were enrolled. Tolerability was excellent, with only 3 mild local reactions. After weekly injections, 11 patients achieved tumor regression, 8 had stable disease, and 1 experienced progressive disease; 9 patients received autologous serum, with response improvement in 4 cases (3 complete responses, 1 partial response). At the end of treatment, 12 patients achieved a complete remission, and 1 achieved a partial response, with an overall response rate of 65% (95% confidence interval, 45-85). At a median follow-up of 42 months (range, 10-78), 12 patients remain relapse free, with 5-year progression-free survival and time-to-next-treatment rates of 59% ± 11% and 69% ± 11%, respectively. Three patients with local relapse were retreated with intralesional rituximab and serum; 2 achieved a complete response that lasted 25+ and 38+ months. Thus, intralesional rituximab is a safe and active therapy in patients with relapsed conjunctival MALT lymphoma. The addition of autologous serum improves response in some cases. Retreatment of local relapses can result in a second durable remission.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum
- Date Crossref
- 17/03/2020
- Éditeur
- American Society of Hematology
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Ophthalmology Associates (United States) pays non établi dans la noticeInstitution
-
Istituti di Ricovero e Cura a Carattere Scientifico pays non établi dans la noticeÉtablissement de santé
-
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele pays non établi dans la noticeÉtablissement de santé
-
University of Pavia Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Azienda Sanitaria Universitaria Integrata di Trieste pays non établi dans la noticeÉtablissement de santé
-
University of Verona Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte pays non établi dans la noticeÉtablissement de santé
-
Vita-Salute San Raffaele University pays non établi dans la noticeUniversité ou école supérieure
-
Lymphoma Unit pays non établi dans la noticeInstitution
-
Ophthalmology Unit pays non établi dans la noticeInstitution
-
IRCCS San Raffaele Scientific Institute Pharmacy Unit pays non établi dans la noticeStructure de recherche
-
Division of Hematology pays non établi dans la noticeInstitution
Ophthalmology Associates (United States), Istituti di Ricovero e Cura a Carattere Scientifico et Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.